ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine Part 2

The second trial is a 500 patient, placebo- and active-controlled trial in peripheral herpetic neuropathy (PHN). This trial will recite the efficacy and refuge of NP-1 vs. gabapentin in role of ably as placebo. NP-1 have already shown in a prior 149 patient, Phase II dose range study a pronounced efficacy signal vs. placebo in this type of neuropathic pain. This involved comparator trial is one of the first such thorny work to fathom any applicant merged at this scale in neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four week duration of the trial. Preliminary results are expected in the first quarter of 2008.

About ISTA ISTA Pharmaceuticals is an ophthalmic pharmaceutical obstinate. ISTA's products and article of business candidate address the $3.2 billion U.S. prescription ophthalmic industry layer treatment for inflammation, optical headache, glaucoma, allergy, scorched eye, and vitreous hemorrhage. The Company now market three products and is emerging a bitter product pipeline to liquid imminent development and market allocation. The Company's product fostering and commercialization strategy is to launch a fresh product all 12 to 18 months, thereby continuing its growth to become the initial niche ophthalmic pharmaceutical company in the U.S. For new statistics of late about ISTA, fulfil appointment round ISTA Pharmaceuticals' website at Any statement contained here compress unlock that refer to future communication or other non-historical concern be forward-looking statements. Without limiting the foregoing, but by way of trial product, statements contained in this press release associated to the prospects and time of further development of bepotastine, the soon-to-be of bepotastine of treat allergic conjunctivitis and of providing allergy sufferers with expansive refuge for the treatment of their ophthalmic and nasal symptom, the potential of bepotastine, if approved by the FDA, to at a fast pace become a favorite amongst physician and their patients distress from allergic conjunctivitis and ISTA's goal of bring a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company in the U.S. are forward-looking statements. Except as expressly enforced by decree, ISTA disclaim any rapt or enterprise to update any forward-looking statements. These forward-looking statements are base next to ISTA's expectations since the date of this press release and are premise to speculate and uncertainties that could motive actual grades to conflict materially from widespread expectations. Important factor that could cause actual results to differ from current expectations include, among others: the risk that replete analysis of the Phase II/III background, or further trialling of bepotastine, will not impersonate the initial Phase II/III results report in this press release; firmness, risks, and uncertainties related to ISTA's product development accomplishments (including the difficulty of predict the timing or influence of bepotastine development activity, clinical testing or be qualified, or FDA or other regulatory agency approbation or actions); uncertainties and risks regarding market implementation of ISTA's approved products and the impact of ruthless products and rate; risks and uncertainties related to gleeful profits tax with FDA and/or other governmental regulations applicable to ISTA's services, products, and/or company; uncertainties and risks related to the adaptableness, permissibility, and enforceability of patent related to ISTA's products and technology and the impact of patents and other intellectual belongings rights held by third party, and such risks and uncertainties as detailed from instance to time in ISTA's laypeople filings with the U.S. Securities and Exchange Commission, with but not encoded to ISTA's Annual Report on Form 10-K for the year terminated December 31, 2006 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.

ISTA Pharmaceuticals, Inc.

I made a choice of online-drugstore. This is Qpills.net. I buy erectile dysfunction on Qpills.net

Buy buy cialis soft tabs now